Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems
Background: Schistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-pr...
- Autores:
-
Vicente B.
López-Abán J.
Rojas Caraballo, Jose Vicente
Del Olmo E.
Fernández-Soto P.
Muro A.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2016
- Institución:
- Universidad Cooperativa de Colombia
- Repositorio:
- Repositorio UCC
- Idioma:
- OAI Identifier:
- oai:repository.ucc.edu.co:20.500.12494/41841
- Acceso en línea:
- https://doi.org/10.16925/sp.v9i18.548
https://revistas.unab.edu.co/index.php/medunab/article/view/2272/2806
https://hdl.handle.net/20.500.12494/41841
- Palabra clave:
- fatty acid binding protein
gamma interferon
immunoglobulin E antibody
immunoglobulin G antibody
immunoglobulin G1 antibody
immunoglobulin G2a antibody
immunoglobulin M antibody
immunomodulating agent
interleukin 2
interleukin 4
interleukin 6
Schistosoma vaccine
tumor necrosis factor alpha
fatty acid binding protein
helminth antibody
helminth protein
interleukin 2
interleukin 4
recombinant protein
animal experiment
animal model
animal tissue
antibody response
Article
Baculoviridae
cercaria
controlled study
cytokine production
Escherichia coli
Fasciola hepatica
female
intestine
mouse
nonhuman
parasite load
schistosomiasis mansoni
spleen cell
animal
Bagg albino mouse
cross protection
drug delivery system
Fasciola hepatica
genetics
human
immunology
parasitology
schistosomiasis mansoni
vaccination
Animals
Antibodies
Helminth
Cross Protection
Drug Delivery Systems
Fasciola hepatica
Fatty Acid-Binding Proteins
Female
Helminth Proteins
H
- Rights
- closedAccess
- License
- http://purl.org/coar/access_right/c_14cb
id |
COOPER2_8c530ebff29c0939a09a83a02e9e2c76 |
---|---|
oai_identifier_str |
oai:repository.ucc.edu.co:20.500.12494/41841 |
network_acronym_str |
COOPER2 |
network_name_str |
Repositorio UCC |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems |
title |
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems |
spellingShingle |
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems fatty acid binding protein gamma interferon immunoglobulin E antibody immunoglobulin G antibody immunoglobulin G1 antibody immunoglobulin G2a antibody immunoglobulin M antibody immunomodulating agent interleukin 2 interleukin 4 interleukin 6 Schistosoma vaccine tumor necrosis factor alpha fatty acid binding protein helminth antibody helminth protein interleukin 2 interleukin 4 recombinant protein animal experiment animal model animal tissue antibody response Article Baculoviridae cercaria controlled study cytokine production Escherichia coli Fasciola hepatica female intestine mouse nonhuman parasite load schistosomiasis mansoni spleen cell animal Bagg albino mouse cross protection drug delivery system Fasciola hepatica genetics human immunology parasitology schistosomiasis mansoni vaccination Animals Antibodies Helminth Cross Protection Drug Delivery Systems Fasciola hepatica Fatty Acid-Binding Proteins Female Helminth Proteins H |
title_short |
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems |
title_full |
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems |
title_fullStr |
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems |
title_full_unstemmed |
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems |
title_sort |
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems |
dc.creator.fl_str_mv |
Vicente B. López-Abán J. Rojas Caraballo, Jose Vicente Del Olmo E. Fernández-Soto P. Muro A. |
dc.contributor.author.none.fl_str_mv |
Vicente B. López-Abán J. Rojas Caraballo, Jose Vicente Del Olmo E. Fernández-Soto P. Muro A. |
dc.subject.spa.fl_str_mv |
fatty acid binding protein gamma interferon immunoglobulin E antibody immunoglobulin G antibody immunoglobulin G1 antibody immunoglobulin G2a antibody immunoglobulin M antibody immunomodulating agent interleukin 2 interleukin 4 interleukin 6 Schistosoma vaccine tumor necrosis factor alpha fatty acid binding protein helminth antibody helminth protein interleukin 2 interleukin 4 recombinant protein animal experiment animal model animal tissue antibody response Article Baculoviridae cercaria controlled study cytokine production Escherichia coli Fasciola hepatica female intestine mouse nonhuman parasite load schistosomiasis mansoni spleen cell animal Bagg albino mouse cross protection drug delivery system Fasciola hepatica genetics human immunology parasitology schistosomiasis mansoni vaccination Animals Antibodies Helminth Cross Protection Drug Delivery Systems Fasciola hepatica Fatty Acid-Binding Proteins Female Helminth Proteins H |
topic |
fatty acid binding protein gamma interferon immunoglobulin E antibody immunoglobulin G antibody immunoglobulin G1 antibody immunoglobulin G2a antibody immunoglobulin M antibody immunomodulating agent interleukin 2 interleukin 4 interleukin 6 Schistosoma vaccine tumor necrosis factor alpha fatty acid binding protein helminth antibody helminth protein interleukin 2 interleukin 4 recombinant protein animal experiment animal model animal tissue antibody response Article Baculoviridae cercaria controlled study cytokine production Escherichia coli Fasciola hepatica female intestine mouse nonhuman parasite load schistosomiasis mansoni spleen cell animal Bagg albino mouse cross protection drug delivery system Fasciola hepatica genetics human immunology parasitology schistosomiasis mansoni vaccination Animals Antibodies Helminth Cross Protection Drug Delivery Systems Fasciola hepatica Fatty Acid-Binding Proteins Female Helminth Proteins H |
description |
Background: Schistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-protection against trematode infections. This study reports the immunoprotection induced by cross-reacting Fasciola hepatica FABP, native (nFh12) and recombinantly expressed using two different expression systems Escherichia coli (rFh15) and baculovirus (rFh15b) against Schistosoma mansoni infection. Methods: BALB/c mice were vaccinated with native nFh12 or recombinant rFh15 and rFh15 FABP from F. hepatica formulated in adjuvant adaptation (ADAD) system with natural or chemical synthesised immunomodulators (PAL and AA0029) and then challenged with 150 cercariae of S. mansoni. Parasite burden, hepatic lesions and antibody response were studied in vaccination trials. Furthermore differences between rFh15 and rFh15b immunological responses (cytokine production, splenocyte population and antibody levels) were studied. Results: Vaccination with nFh12 induced significant reductions in worm burden (83 %), eggs in tissues (82-92 %) and hepatic lesions (85 %) compared to infected controls using PAL. Vaccination with rFh15 showed lower total worm burden (56-64 %), eggs in the liver (21-61 %), eggs in the gut (30-77 %) and hepatic damage (67-69 %) using PAL and AA0029 as immunomodulators. In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60 %, respectively), and hepatic lesions (45 %). We observed a significant rise in TNFa, IL-6, IL-2, IL-4 and high antibody response (IgG, IgG1, IgG2a, IgM and IgE) in mice immunised with either rFh15 or rFh15b. Moreover, mice immunised with rFh15b showed an increase in IFN? and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15. Conclusions: Higher level of protection is obtained by using Fasciola hepatica-derived FABP protein against Schistosoma mansoni infection. Native FABP is more effective than both recombinant systems. It could be due to post-translational modifications or FABP isoform or changes in the recombinant proteins. © 2016 Vicente et al. |
publishDate |
2016 |
dc.date.issued.none.fl_str_mv |
2016 |
dc.date.accessioned.none.fl_str_mv |
2021-12-16T22:15:50Z |
dc.date.available.none.fl_str_mv |
2021-12-16T22:15:50Z |
dc.type.none.fl_str_mv |
Artículo |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.coarversion.none.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.redcol.none.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
dc.type.version.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://doi.org/10.16925/sp.v9i18.548 https://revistas.unab.edu.co/index.php/medunab/article/view/2272/2806 |
dc.identifier.issn.spa.fl_str_mv |
17563305 |
dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12494/41841 |
dc.identifier.bibliographicCitation.spa.fl_str_mv |
Vicente B,López J,Rojas J,Del Olmo E,Fernández P,Muro A. Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems. Parasit Vectors. 2016. 9. (1):p. 216-216. . |
url |
https://doi.org/10.16925/sp.v9i18.548 https://revistas.unab.edu.co/index.php/medunab/article/view/2272/2806 https://hdl.handle.net/20.500.12494/41841 |
identifier_str_mv |
17563305 Vicente B,López J,Rojas J,Del Olmo E,Fernández P,Muro A. Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems. Parasit Vectors. 2016. 9. (1):p. 216-216. . |
dc.relation.ispartofjournal.spa.fl_str_mv |
PARASITE VECTOR |
dc.rights.accessrights.none.fl_str_mv |
info:eu-repo/semantics/closedAccess |
dc.rights.coar.none.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
eu_rights_str_mv |
closedAccess |
rights_invalid_str_mv |
http://purl.org/coar/access_right/c_14cb |
dc.format.extent.spa.fl_str_mv |
216-216 |
dc.publisher.spa.fl_str_mv |
BioMed Central Ltd. |
institution |
Universidad Cooperativa de Colombia |
repository.name.fl_str_mv |
Repositorio Institucional Universidad Cooperativa de Colombia |
repository.mail.fl_str_mv |
bdigital@metabiblioteca.com |
_version_ |
1814246930517065728 |
spelling |
Vicente B.López-Abán J.Rojas Caraballo, Jose VicenteDel Olmo E.Fernández-Soto P.Muro A.2021-12-16T22:15:50Z2021-12-16T22:15:50Z2016https://doi.org/10.16925/sp.v9i18.548https://revistas.unab.edu.co/index.php/medunab/article/view/2272/280617563305https://hdl.handle.net/20.500.12494/41841Vicente B,López J,Rojas J,Del Olmo E,Fernández P,Muro A. Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems. Parasit Vectors. 2016. 9. (1):p. 216-216. .Background: Schistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-protection against trematode infections. This study reports the immunoprotection induced by cross-reacting Fasciola hepatica FABP, native (nFh12) and recombinantly expressed using two different expression systems Escherichia coli (rFh15) and baculovirus (rFh15b) against Schistosoma mansoni infection. Methods: BALB/c mice were vaccinated with native nFh12 or recombinant rFh15 and rFh15 FABP from F. hepatica formulated in adjuvant adaptation (ADAD) system with natural or chemical synthesised immunomodulators (PAL and AA0029) and then challenged with 150 cercariae of S. mansoni. Parasite burden, hepatic lesions and antibody response were studied in vaccination trials. Furthermore differences between rFh15 and rFh15b immunological responses (cytokine production, splenocyte population and antibody levels) were studied. Results: Vaccination with nFh12 induced significant reductions in worm burden (83 %), eggs in tissues (82-92 %) and hepatic lesions (85 %) compared to infected controls using PAL. Vaccination with rFh15 showed lower total worm burden (56-64 %), eggs in the liver (21-61 %), eggs in the gut (30-77 %) and hepatic damage (67-69 %) using PAL and AA0029 as immunomodulators. In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60 %, respectively), and hepatic lesions (45 %). We observed a significant rise in TNFa, IL-6, IL-2, IL-4 and high antibody response (IgG, IgG1, IgG2a, IgM and IgE) in mice immunised with either rFh15 or rFh15b. Moreover, mice immunised with rFh15b showed an increase in IFN? and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15. Conclusions: Higher level of protection is obtained by using Fasciola hepatica-derived FABP protein against Schistosoma mansoni infection. Native FABP is more effective than both recombinant systems. It could be due to post-translational modifications or FABP isoform or changes in the recombinant proteins. © 2016 Vicente et al.josev.rojas@campusucc.edu.co216-216BioMed Central Ltd.fatty acid binding proteingamma interferonimmunoglobulin E antibodyimmunoglobulin G antibodyimmunoglobulin G1 antibodyimmunoglobulin G2a antibodyimmunoglobulin M antibodyimmunomodulating agentinterleukin 2interleukin 4interleukin 6Schistosoma vaccinetumor necrosis factor alphafatty acid binding proteinhelminth antibodyhelminth proteininterleukin 2interleukin 4recombinant proteinanimal experimentanimal modelanimal tissueantibody responseArticleBaculoviridaecercariacontrolled studycytokine productionEscherichia coliFasciola hepaticafemaleintestinemousenonhumanparasite loadschistosomiasis mansonispleen cellanimalBagg albino mousecross protectiondrug delivery systemFasciola hepaticageneticshumanimmunologyparasitologyschistosomiasis mansonivaccinationAnimalsAntibodiesHelminthCross ProtectionDrug Delivery SystemsFasciola hepaticaFatty Acid-Binding ProteinsFemaleHelminth ProteinsHProtection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systemsArtículohttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1http://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionPARASITE VECTORinfo:eu-repo/semantics/closedAccesshttp://purl.org/coar/access_right/c_14cbPublication20.500.12494/41841oai:repository.ucc.edu.co:20.500.12494/418412024-08-20 16:19:08.877metadata.onlyhttps://repository.ucc.edu.coRepositorio Institucional Universidad Cooperativa de Colombiabdigital@metabiblioteca.com |